Effect of zoledronic acid on the vertebral body bone mineral density after instrumented intervertebral fusion in postmenopausal women with osteoporosis

Published: 2 June 2021| Version 1 | DOI: 10.17632/n7xzp8c9ks.1
xiaoxiang li


This study evaluated the effect of anti-osteoporosis treatment with intravenous zoledronic acid during the perioperative period, on the adjacent vertebral body bone mineral density (BMD) after spinal fusion surgery in postmenopausal women with osteoporosis. All data were collected retrospectively from patients' medical records using standardized forms, including: demographics (age, BMI, years since menopause); surgical details of levels included (fusion level and cephalad levels); and BMD values. BMD values (g/cm2) were recorded for the overall lumbar spine, for the levels cephalad to the fused segments, and the femoral neck. The group 0 represents the treated group and group 1 represents the untreated group. The table 1 shows the data about the description of demographic and surgery information of treated group and untreated group. Additionally, the table 2 shows the information about cephalad adjacent vertebral and femoral neck BMD value change. The conclusion shows that perioperative zoledronic acid treatment may offer protection against a significant decrease in BMD of cephalad vertebrae after spinal fusion surgery among postmenopausal women with osteoporosis.



Retrospective Study, Osteoporosis, Bone Mineral Density, Spinal Fusion, Medical Record